Free Newsletter
UK doctors warned over Novartis' Prexige
Health activists in the UK are taking it upon themselves to warn doctors away from Prexige, Novartis' Cox-2 arthritis remedy. Drug regulators in Britain and Europe are sifting through safety data on the painkiller after eight cases of severe liver damage caused Australia to ban it.
The UK says it's received 16 adverse reactions reports, including one of a liver reaction. But, the regulators stress, the Australian patients who suffered--and in two cases, died--from the drug's effect on their liver were taking double the 100 mg dose routinely prescribed in the UK. According to Novartis, Australia was the only country in the world where 200 mg once-daily tablets were sold. Unfortunately for Novartis, the dosage distinction may be lost on consumers--and the activists who advise them.
- read the report from The Guardian
Related Article:
Australia bans Novartis' Prexige. Report
Fresh danger signs for Cox-2 inhibitors. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: